nach oben

memo - Magazine of European Medical Oncology

Tipp

Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes

verfasst von: Ursula M. Vogl, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

The year 2018 is an exciting time to work as a uro-oncologist. Therapies have developed rapidly in the last year. …

Vorheriger Artikel Revival of anti-angiogenic therapies in cancer

Nächster Artikel In need of special care: adolescent and young adult patients with cancer

Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95(6):691–8. CrossRefPubMedPubMedCentral

Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197(1):44–9. CrossRefPubMed

Cornford P, Bellmunt J, Bolla M, Briers E, De SM, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42. CrossRefPubMed

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73(2):178–211. CrossRefPubMed

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De SM, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29. CrossRefPubMed

Mottet N, De SM, Briers E, Bourke L, Gillessen S, Grummet JP, et al. Updated guidelines for metastatic hormone-sensitive prostate cancer: abiraterone acetate combined with castration is another standard. Eur Urol. 2017; https://doi.org/10.1016/j.eururo.2017.09.029.

Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–62. CrossRefPubMed

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. CrossRefPubMedPubMedCentral

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. CrossRefPubMedPubMedCentral

10.

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60. CrossRefPubMed

11.

Sweeney C, Davis I et al. Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET), NCT02446405. 2018.

12.

Escudier B, Tannir N, McDermott D. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metatstatic renal cell carcinoma (mRCC), including IMDC risk and PDL-1 expression subgroups. 2018.

13.

Bellmunt J, Bajorin DF. Pembrolizumab for advanced urothelial carcinoma. N Engl J Med. 2017;376(23):2304–8. PubMed

14.

Bellmunt J, de WR, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. CrossRefPubMedPubMedCentral

15.

Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De GU, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; https://doi.org/10.1016/S0140-6736(17)33297-X.

16.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. CrossRefPubMedPubMedCentral

17.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. CrossRefPubMed

18.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–77. CrossRefPubMed

19.

Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61. CrossRefPubMed

20.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. CrossRefPubMedPubMedCentral

Titel: Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
verfasst von: Ursula M. Vogl, MD
Publikationsdatum: 23.02.2018
Verlag: Springer Vienna
Schlagwort: Onkologie
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0393-1

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes

Excerpt

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Antiangiogenic therapies in ovarian cancer

Short overview on the current standard of treatment in newly diagnosed multiple myeloma

My burning issues in the neoadjuvant treatment for breast cancer

Local therapy of stage IV renal cell cancer: a case report

memo—publisher’s report 2017

Cell free nucleic acids as diagnostic and prognostic marker in leukemia